Acute Hyperglycemia Associated with Anti-Cancer Medication.

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 10.33

Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20

Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation (2006) 3.00

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64

Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol (2010) 2.46

Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol (2014) 2.29

Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol (2005) 2.15

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95

Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med (2009) 1.94

Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol (2010) 1.80

Glucocorticoid-induced hyperglycemia. Endocr Pract (2009) 1.74

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73

Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst (2012) 1.72

Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia (2012) 1.55

Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 1.42

Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol (2012) 1.41

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother (2016) 1.40

Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci (2008) 1.38

Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab (2011) 1.34

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 1.33

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer (2014) 1.32

Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol (2009) 1.30

Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol (2014) 1.25

Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy (2004) 1.20

Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract (2006) 1.19

Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer (2007) 1.10

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care (2015) 1.09

Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer. Prostate (2009) 0.98

Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol (2001) 0.94

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes. Diabetes Care (2015) 0.90

Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2005) 0.87

Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Colorectal Dis (2013) 0.86

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig (2016) 0.85

Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia. Lancet (2004) 0.84

Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation. Pediatr Blood Cancer (2015) 0.83

Incidences of diabetes and prediabetes among female adult breast cancer patients after systemic treatment. Med Oncol (2013) 0.81

Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Support Care Cancer (2013) 0.80

Hemoglobin A1c and the relationship to stage and grade of endometrial cancer. Arch Gynecol Obstet (2012) 0.77

14. Diabetes Care in the Hospital. Diabetes Care (2017) 0.77

Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol (2009) 0.76